Welcome to our dedicated page for LB Pharmaceuticals news (Ticker: LBRX), a resource for investors and traders seeking the latest updates and insights on LB Pharmaceuticals stock.
LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (NASDAQ:LBRX) has announced the pricing of its upsized initial public offering, offering 19,000,000 shares of common stock at $15.00 per share. The company expects to raise $285.0 million in gross proceeds before deducting underwriting costs and other expenses.
The IPO includes a 30-day option for underwriters to purchase up to 2,850,000 additional shares. Trading is set to commence on the Nasdaq Global Market on September 11, 2025, under the ticker symbol "LBRX". The offering is expected to close on September 12, 2025, with Leerink Partners, Piper Sandler, and Stifel serving as joint bookrunning managers.